Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00002003 · ClinicalTrials.gov registry record · Phase 2
Phase II Study of Novantrone(R) (Mitoxantrone) and Etoposide in Patients With HIV Associated Large Cell and Immunoblastic Lymphomas
A Phase 2 study, sponsored by Lederle Laboratories.
- Completed
- Registry status
- Phase 2
- Development phase
NCT00002003: Completed Phase 2 study, sponsored by Lederle Laboratories.
NCT00002003 is a Phase 2 study that has completed, run by Lederle Laboratories. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00002003, a Phase 2 study, has completed, sponsored by Lederle Laboratories.
- COMPLETED
- Registry status
- Phase 2
- Development phase
Study Summary
To determine the efficacy and toxicity of the combination of mitoxantrone hydrochloride ( Novantrone ) and etoposide in the treatment of patients with HIV associated lymphomas.
Interventions
- DRUG Etoposide
- DRUG Mitoxantrone hydrochloride
Trial Details
| Field | Value |
|---|---|
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00002003
The ClinicalTrials.gov registry entry for NCT00002003 describes a study currently listed as completed, categorized as Phase 2. An enrollment target was not published in the registry record, which is common for early-stage or observational entries. The listed sponsor is Lederle Laboratories, which has 6 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Etoposide is the first listed.
NCT00002003 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00002003 about?
NCT00002003 is a clinical study titled "Phase II Study of Novantrone(R) (Mitoxantrone) and Etoposide in Patients With HIV Associated Large Cell and Immunoblastic Lymphomas". To determine the efficacy and toxicity of the combination of mitoxantrone hydrochloride ( Novantrone ) and etoposide in the treatment of patients with HIV associated lymphomas.
What is the current status of trial NCT00002003?
This trial is currently completed. It is a Phase 2 study.
What interventions are being tested in trial NCT00002003?
The interventions under investigation include: Etoposide (DRUG), Mitoxantrone hydrochloride (DRUG).
Who is sponsoring clinical trial NCT00002003?
This trial is sponsored by Lederle Laboratories, which has 6 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.